Literature DB >> 31527241

A higher-order configuration of the heterodimeric DOT1L-AF10 coiled-coil domains potentiates their leukemogenenic activity.

Xiaosheng Song1,2,3, Liuliu Yang2,3, Mingzhu Wang4, Yue Gu1, Buqing Ye2, Zusen Fan2,3, Rui-Ming Xu5,3, Na Yang6.   

Abstract

Chromosomal translocations of MLL1 (Mixed Lineage Leukemia 1) yield oncogenic chimeric proteins containing the N-terminal portion of MLL1 fused with distinct partners. The MLL1-AF10 fusion causes leukemia through recruiting the H3K79 histone methyltransferase DOT1L via AF10's octapeptide and leucine zipper (OM-LZ) motifs. Yet, the precise interaction sites in DOT1L, detailed interaction modes between AF10 and DOT1L, and the functional configuration of MLL1-AF10 in leukeomogenesis remain unknown. Through a combined approach of structural and functional analyses, we found that the LZ domain of AF10 interacts with the coiled-coil domains of DOT1L through a conserved binding mode and discovered that the C-terminal end of the LZ domain and the OM domain of AF10 mediate the formation of a DOT1L-AF10 octamer via tetramerization of the binary complex. We reveal that the oligomerization ability of the DOT1L-AF10 complex is essential for MLL1-AF10's leukemogenic function. These findings provide insights into the molecular basis of pathogenesis by MLL1 rearrangements.

Entities:  

Keywords:  DOT1L; MLL1–AF10 fusion; leukemogenesis; octamerization; structure

Year:  2019        PMID: 31527241      PMCID: PMC6778216          DOI: 10.1073/pnas.1904672116

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  27 in total

1.  Biochemical analyses of the AF10 protein: the extended LAP/PHD-finger mediates oligomerisation.

Authors:  B Linder; R Newman; L K Jones; S Debernardi; B D Young; P Freemont; C P Verrijzer; V Saha
Journal:  J Mol Biol       Date:  2000-06-02       Impact factor: 5.469

2.  A carboxy-terminal domain of ELL is required and sufficient for immortalization of myeloid progenitors by MLL-ELL.

Authors:  J F DiMartino; T Miller; P M Ayton; T Landewe; J L Hess; M L Cleary; A Shilatifard
Journal:  Blood       Date:  2000-12-01       Impact factor: 22.113

3.  A role for the MLL fusion partner ENL in transcriptional elongation and chromatin modification.

Authors:  Dorothee Mueller; Christian Bach; Deniz Zeisig; Maria-Paz Garcia-Cuellar; Sara Monroe; Arun Sreekumar; Rong Zhou; Alexey Nesvizhskii; Arul Chinnaiyan; Jay L Hess; Robert K Slany
Journal:  Blood       Date:  2007-09-12       Impact factor: 22.113

4.  Hoxa9 transforms primary bone marrow cells through specific collaboration with Meis1a but not Pbx1b.

Authors:  E Kroon; J Krosl; U Thorsteinsdottir; S Baban; A M Buchberg; G Sauvageau
Journal:  EMBO J       Date:  1998-07-01       Impact factor: 11.598

5.  Degree of recruitment of DOT1L to MLL-AF9 defines level of H3K79 Di- and tri-methylation on target genes and transformation potential.

Authors:  Aravinda Kuntimaddi; Nicholas J Achille; Jeremy Thorpe; Alyson A Lokken; Ritambhara Singh; Charles S Hemenway; Mazhar Adli; Nancy J Zeleznik-Le; John H Bushweller
Journal:  Cell Rep       Date:  2015-04-23       Impact factor: 9.423

6.  hDOT1L links histone methylation to leukemogenesis.

Authors:  Yuki Okada; Qin Feng; Yihui Lin; Qi Jiang; Yaqiang Li; Vernon M Coffield; Lishan Su; Guoliang Xu; Yi Zhang
Journal:  Cell       Date:  2005-04-22       Impact factor: 41.582

7.  AF10 regulates progressive H3K79 methylation and HOX gene expression in diverse AML subtypes.

Authors:  Aniruddha J Deshpande; Anagha Deshpande; Amit U Sinha; Liying Chen; Jenny Chang; Ali Cihan; Maurizio Fazio; Chun-Wei Chen; Nan Zhu; Richard Koche; Liuda Dzhekieva; Gloria Ibáñez; Stuart Dias; Deepti Banka; Andrei Krivtsov; Minkui Luo; Robert G Roeder; James E Bradner; Kathrin M Bernt; Scott A Armstrong
Journal:  Cancer Cell       Date:  2014-11-20       Impact factor: 31.743

Review 8.  Molecular mechanisms of leukemogenesis mediated by MLL fusion proteins.

Authors:  P M Ayton; M L Cleary
Journal:  Oncogene       Date:  2001-09-10       Impact factor: 9.867

9.  Disruptor of telomeric silencing-1 is a chromatin-specific histone H3 methyltransferase.

Authors:  Nicolas Lacoste; Rhea T Utley; Joanna M Hunter; Guy G Poirier; Jacques Côte
Journal:  J Biol Chem       Date:  2002-07-03       Impact factor: 5.157

10.  Structural and functional analysis of the DOT1L-AF10 complex reveals mechanistic insights into MLL-AF10-associated leukemogenesis.

Authors:  Heng Zhang; Bo Zhou; Su Qin; Jing Xu; Rachel Harding; Wolfram Tempel; Vinod Nayak; Yanjun Li; Peter Loppnau; Yali Dou; Jinrong Min
Journal:  Genes Dev       Date:  2018-03-21       Impact factor: 11.361

View more
  7 in total

1.  Computational modeling reveals key molecular properties and dynamic behavior of disruptor of telomeric silencing 1-like (DOT1L) and partnering complexes involved in leukemogenesis.

Authors:  Timothy J Stodola; Young-In Chi; Thiago M De Assuncao; Elise N Leverence; Swarnendu Tripathi; Nikita R Dsouza; Angela J Mathison; Brian F Volkman; Brian C Smith; Gwen Lomberk; Michael T Zimmermann; Raul Urrutia
Journal:  Proteins       Date:  2021-09-12

Review 2.  The language of chromatin modification in human cancers.

Authors:  Shuai Zhao; C David Allis; Gang Greg Wang
Journal:  Nat Rev Cancer       Date:  2021-05-17       Impact factor: 60.716

3.  The lncRNA LAMP5-AS1 drives leukemia cell stemness by directly modulating DOT1L methyltransferase activity in MLL leukemia.

Authors:  Wen-Tao Wang; Tian-Qi Chen; Zhan-Cheng Zeng; Qi Pan; Wei Huang; Cai Han; Ke Fang; Lin-Yu Sun; Qian-Qian Yang; Dan Wang; Xue-Qun Luo; Yu-Meng Sun; Yue-Qin Chen
Journal:  J Hematol Oncol       Date:  2020-06-17       Impact factor: 17.388

Review 4.  Targeting Chromatin Complexes in Myeloid Malignancies and Beyond: From Basic Mechanisms to Clinical Innovation.

Authors:  Florian Perner; Scott A Armstrong
Journal:  Cells       Date:  2020-12-21       Impact factor: 6.600

5.  AF10 (MLLT10) prevents somatic cell reprogramming through regulation of DOT1L-mediated H3K79 methylation.

Authors:  Deniz Uğurlu-Çimen; Deniz Odluyurt; Kenan Sevinç; Nazlı Ezgi Özkan-Küçük; Burcu Özçimen; Deniz Demirtaş; Eray Enüstün; Can Aztekin; Martin Philpott; Udo Oppermann; Nurhan Özlü; Tamer T Önder
Journal:  Epigenetics Chromatin       Date:  2021-07-02       Impact factor: 4.954

6.  The role of the PZP domain of AF10 in acute leukemia driven by AF10 translocations.

Authors:  Brianna J Klein; Anagha Deshpande; Khan L Cox; Fan Xuan; Mohamad Zandian; Karina Barbosa; Sujita Khanal; Qiong Tong; Yi Zhang; Pan Zhang; Amit Sinha; Stefan K Bohlander; Xiaobing Shi; Hong Wen; Michael G Poirier; Aniruddha J Deshpande; Tatiana G Kutateladze
Journal:  Nat Commun       Date:  2021-07-05       Impact factor: 14.919

Review 7.  Targeting the histone H3 lysine 79 methyltransferase DOT1L in MLL-rearranged leukemias.

Authors:  Yan Yi; Shenglei Ge
Journal:  J Hematol Oncol       Date:  2022-03-24       Impact factor: 17.388

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.